Xofluza Generic Name & Formulations
Baloxavir marboxil 40mg, 80mg; tabs.
Polymerase acidic (PA) endonuclease inhibitor.
Treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than 48hrs and who are otherwise healthy patients ≥5yrs of age, or patients ≥12yrs of age who are at high risk of developing influenza-related complications. Post-exposure prophylaxis of influenza in individuals ≥5yrs of age following contact with an individual who has influenza.
Limitations of Use
Consider available information on drug susceptibility patterns for circulating influenza strains when deciding whether to use.
Xofluza Dosage and Administration
Adults and Children
<5yrs (treatment or post-exposure prophylaxis); <12yrs (treatment of high risk of developing influenza-related complications): not established. ≥5yrs: (20–<80kg): 40mg as a single dose; (≥80kg): 80mg as a single dose.
Xofluza Boxed Warnings
Increased risk of treatment-emergent resistance in patients <5yrs of age. Potential secondary bacterial infections; treat appropriately. Pregnancy. Nursing mothers.
Avoid coadministration with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (eg, calcium, iron, magnesium, selenium, or zinc). May reduce efficacy of live attenuated influenza vaccines.
Xofluza Adverse Reactions
Diarrhea, bronchitis, nausea, sinusitis, headache, vomiting; hypersensitivity reactions.
Xofluza Clinical Trials
Xofluza Patient Counseling